Collegium Pharmaceutical, Inc. COLL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| Belbuca | $222.64M+0.4% | $221.65M+1.8% | $217.72M+2.4% | $212.67M+0.2% | $212.26M+0.5% | |
| Jornay PM | $159.21M+7.0% | $148.86M+12.6% | $132.25M+34.4% | $98.4M— | —— | |
| Nucynta ER | $79.53M-1.8% | $80.99M+1.3% | $79.98M+4.0% | $76.94M+0.9% | $76.27M+0.7% | |
| Nucynta IR | $113.97M-1.2% | $115.31M+4.7% | $110.12M+6.4% | $103.5M+1.3% | $102.2M+1.4% | |
| Finite-Lived Intangible Assets, Net by Product | ||||||
| Belbuca | $339.26M-18.2% | $414.66M-15.4% | $490.05M-13.3% | $565.44M-11.8% | $640.84M-10.5% | |
| Jornay PM | $2.14B-3.8% | $2.22B-3.6% | $2.31B-3.5% | $2.39B— | —— | |
| Symproic | $173.64M-4.0% | $180.92M-3.9% | $188.21M-3.7% | $195.49M-3.6% | $202.77M-3.5% | |
| Cost, Amortization by Product | ||||||
| Belbuca | $75.4M0.0% | $75.4M0.0% | $75.4M0.0% | $75.4M0.0% | $75.39M0.0% | |
| Jornay PM | $83.83M0.0% | $83.83M0.0% | $83.83M+21.2% | $69.16M— | —— | |
| Finite-Lived Intangible Asset, Expected Amortization, Year Four by Product | ||||||
| Jornay PM | $335.32M0.0% | $335.32M0.0% | $335.32M0.0% | $335.32M— | —— | |
| Cost by Product | ||||||
| Belbuca | $1.44B0.0% | $1.44B0.0% | $1.44B0.0% | $1.44B0.0% | $1.44B0.0% | |
| Jornay PM | $2.54B0.0% | $2.54B0.0% | $2.54B0.0% | $2.54B— | —— | |
| Symproic | $280M0.0% | $280M0.0% | $280M0.0% | $280M0.0% | $280M0.0% | |
| Finite-Lived Intangible Assets, Accumulated Amortization by Product | ||||||
| Belbuca | $1.1B+7.4% | $1.03B+7.9% | $949.95M+8.6% | $874.56M+9.4% | $799.16M+10.4% | |
| Jornay PM | $402.37M+26.3% | $318.54M+35.7% | $234.71M+55.6% | $150.88M— | —— | |
| Symproic | $106.37M+7.4% | $99.08M+7.9% | $91.79M+8.6% | $84.51M+9.4% | $77.23M+10.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 9 parts — Belbuca, Jornay PM, Nucynta ER AG, Nucynta ER and Nucynta IR AG. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
